Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 2;15(3):e35705.
doi: 10.7759/cureus.35705. eCollection 2023 Mar.

Systemic Immune-Inflammation Index May Predict Mortality in Neuroblastoma

Ilknur Banlı Cesur  1 , Zerrin Özçelik  1
Affiliations

Systemic Immune-Inflammation Index May Predict Mortality in Neuroblastoma

Ilknur Banlı Cesur et al. Cureus. .

Abstract

Introduction: Neuroblastomas (NB) are among the most frequent childhood solid tumors. The link between inflammation and cancer is well understood. Many research studies have been conducted to determine the prognostic importance of inflammatory markers in cancer patients. C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) are all potential inflammation indicators. The purpose of this study is to assess the efficacy of NLR and SII as inflammatory indicators in predicting NB patient survival.

Materials and methods: Patients with NB diagnosed between January 1, 2012 and December 31, 2021 were studied retrospectively, and death was documented. By dividing the number of neutrophils by the number of lymphocytes, the NLR was obtained. The SII was calculated by multiplying the NLR by the platelet count.

Results: 46 patients with NB were included in the study with a mean age of 57.58 months (4.14-170.05). When the patients were analyzed based on mortality the NLR and SII values were statistically significantly increased in the dead group (2.71 (1.22-4.1 ) vs. 1.7 (0.16-5.1); p=0.02; and 677.8 (215-1322) vs. 294.6 (69.49-799.1), respectively; p=0.012). Analysis of the receiver operating curve found that 328.49 is the ideal cutoff value for SII to predict mortality with a sensitivity of 83% and a specificity of 68% (area under the receiver operating characteristic curve = 0.814 (95% confidence interval: 0.671-0.956), p=0.005 ). Analyzing the influence of risk factors on survival using Cox regression analysis, SII was discovered as a significant predictor of survival in the study (HR =1.001, 95% CI =1-1.20; p=0.049).

Conclusion: SII may be used to predict the overall survival of NB patients.

Keywords: inflammation; mortality; neuroblastoma; neutrophil-to-lymphocyte ratio; systemic immune-inflammation index.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. ROC analysis of NLR and SII
NLR: neutrophil to lymphocyte ratio; ROC: receiver operating curve; SII: systemic immune-inflammation index
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Inflammation and cancer: advances and new agents. Crusz SM, Balkwill FR. Nat Rev Clin Oncol. 2015;12:584–596. - PubMed
    1. Cancer-related inflammation. Mantovani A, Allavena P, Sica A, Balkwill F. Nature. 2008;454:436–444. - PubMed
    1. Nutrition, inflammation and cancer. Zitvogel L, Pietrocola F, Kroemer G. Nat Immunol. 2017;18:843–850. - PubMed
    1. The value of C-reactive protein as an independent prognostic indicator for disease-specific survival in patients with soft tissue sarcoma: a meta-analysis. Wang X, Liu S, Zhao X, Fang E, Zhao X. PLoS ONE. 2019;14:0. - PMC - PubMed
    1. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Semeniuk-Wojtaś A, Lubas A, Stec R, Syryło T, Niemczyk S, Szczylik C. Clin Genitourin Cancer. 2018;16:0–93. - PubMed

LinkOut - more resources